← Leaderboards
Wei Zhang
University Of Illinois At Chicago
$5,899,762
Attributed
$12,612,959
Total exposure
11
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,612,959 · 11
By mechanism
R01$5,186,085 · 2
U01$3,844,357 · 2
R21$2,100,753 · 5
R33$1,181,771 · 1
R56$299,993 · 1
Top collaborators
- Brian C-H Chiu16 shared
- Marc Bissonnette6 shared
- Benjamin Derman3 shared
- Shi-Yuan Cheng2 shared
- M Eileen Dolan2 shared
- Lucy Ann Godley2 shared
- Lifang Hou2 shared
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisSamplingEpigenetic ProcessMalignant NeoplasmsCellsBaseModificationTumorGenesNext Generation SequencingCell Free DnaMortalityCytosinePlasmaGene ExpressionInnovationTreatment ResponseProspectiveGenomicsEpigenetic MarkerNeoplastic CellTechnologyResourcesResponse
Grant awards (28)
A non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis$692,491
U01 · FY2025 · CA
Integrating liquid biopsy-based epigenetic and imaging modalities to evaluate disease response in multiple myeloma$654,367
R01 · FY2025 · CA
RNA m6A modifications and treatment response in multiple myeloma$188,244
R21 · FY2025 · CA
Integrating liquid biopsy-based epigenetic and imaging modalities to evaluate disease response in multiple myeloma$631,736
R01 · FY2024 · CA
A highly sensitive linear amplification based DNA methylation profiling technique for clinical cancer research$370,741
R33 · FY2024 · CA
RNA m6A modifications and treatment response in multiple myeloma$241,585
R21 · FY2024 · CA
Integrating liquid biopsy-based epigenetic and imaging modalities to evaluate disease response in multiple myeloma$691,734
R01 · FY2023 · CA
A highly sensitive linear amplification based DNA methylation profiling technique for clinical cancer research$389,864
R33 · FY2023 · CA
Elucidating novel epigenetic modifications implicated in multiple myeloma risk disparities$299,993
R56 · FY2023 · CA
Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma$609,211
R01 · FY2022 · CA
A highly sensitive linear amplification based DNA methylation profiling technique for clinical cancer research$421,166
R33 · FY2022 · CA
Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma$634,955
R01 · FY2021 · CA
Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis$599,788
U01 · FY2021 · CA
Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis$759,227
U01 · FY2020 · CA
Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma$645,738
R01 · FY2020 · CA
Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma$635,981
R01 · FY2019 · CA
Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis$581,794
U01 · FY2019 · CA
Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma$682,363
R01 · FY2018 · CA
Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis$597,821
U01 · FY2018 · CA
Using epigenomic subtyping to understand the racial differences in lymphoma$200,434
R21 · FY2018 · MD
Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis$613,236
U01 · FY2017 · CA
Using epigenomic subtyping to understand the racial differences in lymphoma$254,325
R21 · FY2017 · MD
Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Glioblastomas$165,732
R21 · FY2017 · CA · contact PI
Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Glioblastomas$199,629
R21 · FY2016 · CA · contact PI
Detection of 5-hmC as a Novel Screening Biomarker for Pancreatic Cancer$171,851
R21 · FY2016 · CA · contact PI
Detection of 5-hmC as a Novel Screening Biomarker for Pancreatic Cancer$216,485
R21 · FY2015 · CA · contact PI
Epigenetic and Genetic Dissection of Drug Response$211,858
R21 · FY2012 · HG · contact PI
Epigenetic and Genetic Dissection of Drug Response$250,610
R21 · FY2011 · HG · contact PI